Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS unified agenda

This article was originally published in The Tan Sheet

Executive Summary

FDA will begin reviewing nutrient content "high potency" and "antioxidant" claims this month and plans to complete the work in September 2007, according to the Health & Human Services Department's semi-annual "unified agenda" published in the Dec. 11 Federal Register. FDA also plans to publish a final rule on claims antihistamines can make for the common cold in June 2007, according to the unified agenda. The agency will announce a notice of proposed rulemaking in October 2007 to add Stevens-Johnson warnings on OTC analgesics. It intended to issue the proposed rule in June 2006, according to the previous unified agenda (1"The Tan Sheet" May 15, 2006, p. 8). FDA plans to issue an NPRM in May to "address oral healthcare products used to reduce or prevent dental plaque or gingivitis," the agenda says...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel